ELDN - NASDAQ

Eledon Pharmaceuticals, Inc.

ELDN·NASDAQ

$3.53

+6.0%

HealthcareBiotechnology

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$211.62M

EPS-0.5600

P/E Ratio-2.71

Earnings Date08/06/2026

237.60M

Assets

34%

3Y+156.0%

5Y+20.0%

10Y+698.0%

100.82M

Total Liabilities

70%

3Y+1071.0%

5Y+1430.0%

10Y+3373.0%

136.78M

Total Equity

16%

3Y+62.0%

5Y-28.0%

10Y+409.0%

Eledon Pharmaceuticals, Inc. Funding & Solvency Profile

ELDN · NASDAQ

Current Assets

Cash & Cash Equivalents22.81M

Net Receivables514.00K

Inventory0.00

Other Current Assets1.84M

Total Current Assets136 M

Non-Current Assets

Property, Plant & Equipment613.00K

Goodwill & Intangible Assets32.39M

Long-Term Investments0.00

Other Non-Current Assets68.92M

Total Non-Current Assets70 M

Total Assets

237.60M

Financial Health Analysis

Current Ratio

7.40x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.74x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

117 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

57% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Eledon Pharmaceuticals, Inc. Balance Sheet

ELDN • NASDAQ

Eledon Pharmaceuticals, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	22.8M	20.5M	4.6M	56.4M	84.8M	114.2M	8.8M	13M	17.2M	23.2M	24M	105.3M	31.8M	11.7M
Short-Term Investments	110.5M	119.6M	46.5M	0.0	0.0	0.0	0.0	0.0	0.0	4.2M	39.9M	0.0	0.0	0.0
Cash & Short-Term Investments	133.3M	140.2M	51.1M	56.4M	84.8M	114.2M	8.8M	13M	17.2M	27.4M	64M	105.3M	31.8M	11.7M
Net Receivables	514K	0.0	0.0	0.0	0.0	110K	245K	594K	0.0	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	514K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	0.0	0.0	0.0	0.0	0.0	110K	245K	594K	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	881K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	2.8M	4.9M	3.1M	3.5M	1.3M	881K	674K	1.7M	0.0	70K	12K	425K	235K
Other Current Assets	1.8M	729K	90K	28K	34K	38K	54K	36K	88K	47K	3.2M	2.3M	0.0	0.0
Total Current Assets	135.7M	143.7M	56.1M	59.5M	88.3M	115.6M	10M	14.3M	19M	29.5M	67.2M	107.5M	32.2M	11.9M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	613K	926K	365K	739K	768K	138K	321K	14K	25K	98K	489K	33K	29K	16K
Goodwill	0.0	0.0	0.0	0.0	48.6M	48.6M	0.0	1.9M	1.9M	0.0	0.0	0.0	0.0	0.0
Intangible Assets	32.4M	32.4M	32.4M	32.4M	32.4M	32.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	32.4M	32.4M	32.4M	32.4M	81M	81M	0.0	1.9M	1.9M	0.0	0.0	0.0	0.0	0.0
Long-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	270K	0.0	0.0	0.0
Other Non-Current Assets	68.9M	363K	186K	150K	400K	383K	639K	869K	0.0	120K	45K	200K	80K	20K
Total Non-Current Assets	101.9M	33.7M	32.9M	33.3M	82.2M	81.6M	960K	2.8M	1.9M	218K	804K	233K	109K	36K
Total Assets	237.6M	177.4M	89.1M	92.8M	170.5M	197.2M	10.9M	17M	20.9M	29.8M	68M	107.7M	32.3M	12M
LIABILITIES
CURRENT LIABILITIES
Total Payables	3.6M	5.8M	967K	2.2M	1.8M	1.4M	329K	689K	418K	338K	1.2M	765K	5K	764K
Accounts Payable	3.6M	5.8M	967K	2.2M	1.8M	1.4M	329K	689K	418K	338K	1.2M	765K	5K	764K
Accrued Expenses	0.0	3.8M	542K	3.9M	704K	875K	813K	1.8M	1M	113K	5M	3.5M	2.2M	1.3M
Short Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4M	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	358K	314K	383K	363K	369K	144K	180K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.4M	0.0	0.0	0.0	0.0
Other Current Liabilities	14.4M	1.6M	2M	0.0	1.5M	98K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Current Liabilities	18.3M	11.6M	3.9M	6.5M	4.4M	2.5M	1.3M	2.5M	1.4M	2.8M	6.2M	4.2M	2.2M	2M
NON-CURRENT LIABILITIES
Deferred Tax Liabilities (Non-Current)	2.2M	2.2M	1.8M	0.0	1.8M	4.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	11.4M	44.9M	76.2M	1.8M	0.0	0.0	0.0	0.0	0.0	0.0	88K	0.0	85.3M	49.8M
Total Non-Current Liabilities	13.9M	47.7M	78M	2.1M	2.2M	4.1M	144K	1.8M	1M	84K	88K	0.0	85.3M	49.8M
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.8M	-1M	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations	641K	954K	383K	746K	769K	144K	324K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	100.8M	59.3M	81.9M	8.6M	6.6M	6.6M	1.5M	2.5M	1.4M	2.9M	6.3M	4.2M	87.6M	51.9M
SHAREHOLDERS' EQUITY
Preferred Stock	55.7M	55.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	19K	302.0	107.7M	0.0	0.0
Common Stock	75K	60K	24K	14K	14K	15K	13K	9K	7K	23K	23K	22K	0.0	0.0
Additional Paid-In Capital	482.2M	417.9M	326.6M	287M	278.9M	271M	67M	56.1M	47M	11.4M	193.2M	189.8M	7.8M	7.4M
Retained Earnings	-401.2M	-355.6M	-319.4M	-202.9M	-114.9M	-80.4M	-57.6M	-41.6M	-27.5M	-169.4M	-131.4M	-86.4M	-63.1M	-47.3M
Accumulated Other Comprehensive Income/Loss	24K	26K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1K	-55K	-58K	-43K	-51K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1K	0.0	0.0	43K	51K
Total Stockholders' Equity	136.8M	118.1M	7.2M	84.2M	164M	190.6M	9.5M	14.5M	19.5M	26.9M	61.7M	103.5M	-55.3M	-39.9M
Total Equity	136.8M	118.1M	7.2M	84.2M	164M	190.6M	9.5M	14.5M	19.5M	26.9M	61.7M	103.5M	-55.3M	-39.9M
SUMMARY
Total Liabilities & Equity	237.6M	177.4M	89.1M	92.8M	170.5M	197.2M	10.9M	17M	20.9M	29.8M	68M	107.7M	32.3M	12M
Total Investments	110.5M	119.6M	46.5M	0.0	0.0	0.0	0.0	0.0	0.0	4.2M	39.9M	0.0	0.0	0.0
Total Debt	641K	954K	383K	746K	769K	144K	324K	0.0	0.0	3.4M	0.0	0.0	0.0	0.0
Net Debt	-22.2M	-19.6M	-4.2M	-55.7M	-84.1M	-114.1M	-8.5M	-13M	-17.2M	-19.8M	-24M	-105.3M	-31.8M	-11.7M
Shares Outstanding	59,881,775	59,881,775	59,881,775	59,881,775	59,881,775	59,881,775	59,881,775	59,881,775	59,881,775	59,881,775	59,881,775	59,881,775	59,881,775	59,881,775

SEC Filings

ELDN - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 13, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 13, 2026	May 13, 2026	2026	View Filing
S-3 S-3 N/A	May 01, 2026	May 01, 2026		View Filing
DEF 14A DEF 14A 2026 N/A	April 30, 2026	June 18, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 19, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 19, 2026	March 19, 2026	2026	View Filing
8-K 8-K 2025 N/A	January 02, 2026	December 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 14, 2025	November 14, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 14, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 13, 2025	November 12, 2025	2025	View Filing

Showing 1 to 10 of 202 filings

Related Guides

Blog Categories

Continue your ELDN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.